Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2−/−) mice

Rinaldo, 2002, Fatty acid oxidation disorders, Ann. Rev. Physiol., 64, 477, 10.1146/annurev.physiol.64.082201.154705 Shekhawat, 2003, Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases, Am. J. Physiol., 284, E1098 Wang, 1999, Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency, Proc. Natl. Acad. Sci. USA, 96, 2356, 10.1073/pnas.96.5.2356 Spiekerkoetter, 2003, Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2, J. Inherit. Metab. Disease, 26, 613, 10.1023/A:1025968502527 Longo, 2006, Disorders of carnitine transport and the carnitine cycle, Am. J. Med. Genet., 142, 77, 10.1002/ajmg.c.30087 Peltekova, 2004, Functional variants of OCTN cation transporter genes are associated with Crohn disease, Nat. Genet., 36, 471, 10.1038/ng1339 Silverberg, 2007, Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn’s disease, Eur. J. Hum. Genet., 15, 328, 10.1038/sj.ejhg.5201756 The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature 447 (2007) 661–678. Nezu, 1999, Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter, Nat. Genet., 21, 91, 10.1038/5030 Mamo, 2007, Quantitative evaluation and selection of reference genes in mouse oocytes and embryos cultured in vivo and in vitro, BMC Develop. Biol., 7, 14, 10.1186/1471-213X-7-14 Thakkinstian, 2005, A method for meta-analysis of molecular association studies, Stat. Med., 24, 1291, 10.1002/sim.2010 Altman, 2001 Rioux, 2001, Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease, Nat. Genet., 29, 223, 10.1038/ng1001-223 Newman, 2005, A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease, Gastroenterology, 128, 260, 10.1053/j.gastro.2004.11.056 Fisher, 2006, Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease, Hum. Mutat., 27, 778, 10.1002/humu.20358 Russell, 2006, Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease, Gut., 55, 1114, 10.1136/gut.2005.082107 Noble, 2005, The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn’s disease, Gastroenterology, 129, 1854, 10.1053/j.gastro.2005.09.025 Waller, 2006, Evidence for association of OCTN genes and IBD5 with ulcerative colitis, Gut., 55, 809, 10.1136/gut.2005.084574 Torok, 2005, Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn’s disease, Gut., 54, 1421, 10.1136/gut.2005.066340 Leung, 2006, Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn’s disease in a New Zealand Caucasian cohort, Immunol. Cell Biol., 84, 233, 10.1111/j.1440-1711.2006.01423.x Martinez, 2006, Association of the organic cation transporter OCTN genes with Crohn’s disease in the Spanish population, Eur. J. Hum. Genet., 14, 222, 10.1038/sj.ejhg.5201529 Palmieri, 2006, Variants of OCTN1-2 cation transporter genes are associated with both Crohn’s disease and ulcerative colitis, Aliment. Pharmacol. Ther., 23, 497, 10.1111/j.1365-2036.2006.02780.x Ferraris, 2006, Relationship between CARD15, SLC22A4/5, and DLG5 polymorphisms and early-onset inflammatory bowel diseases: an Italian multicentric study, Inflamm. Bowel. Dis., 12, 355, 10.1097/01.MIB.0000217338.23065.58 Vermeire, 2005, Association of organic cation transporter risk haplotype with perianal penetrating Crohn’s disease but not with susceptibility to IBD, Gastroenterology, 129, 1845, 10.1053/j.gastro.2005.10.006 Gazouli, 2005, Single nucleotide polymorphisms of OCTN1, OCTN2, and DLG5 genes in Greek patients with Crohn’s disease, World J. Gastroenterol., 11, 7525, 10.3748/wjg.v11.i47.7525 Torkvist, 2007, Contribution of the IBD5 locus to Crohn’s disease in the Swedish population, Scand. J. Gastroenterol., 42, 200, 10.1080/00365520600842278 Yamazaki, 2004, Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease, J. Hum. Genet., 49, 664, 10.1007/s10038-004-0204-x Tosa, 2006, Lack of association between IBD5 and Crohn’s disease in Japanese patients demonstrates population-specific differences in inflammatory bowel disease, Scand. J. Gastroenterol., 41, 48, 10.1080/00365520510023864 Bene, 2006, Prevalence of SLC22A4, SLC22A5 and CARD15 gene mutations in Hungarian pediatric patients with Crohn’s disease, World J. Gastroenterol., 12, 5550, 10.3748/wjg.v12.i34.5550 Bene, 2006, Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis, World J. Gastroenterol., 12, 110, 10.3748/wjg.v12.i1.110 Demirkol, 1994, The variation of carnitine content in human blood cells during disease – a study in bacterial infection and inflammatory bowel disease, Eur. J. Pediatr., 153, 565, 10.1007/BF02190659 Roediger, 1990, Selective reduction of fatty acid oxidation in colonocytes: correlation with ulcerative colitis, Lipids, 25, 646, 10.1007/BF02536016 Roediger, 1986, Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation, Br. J. Exp. Pathol., 67, 773 Gasbarrini, 2003, Effects of propionyl-l-carnitine topical irrigation in distal ulcerative colitis: a preliminary report, Hepatogastroenterology, 50, 1385 Johnson, 1992, l-carnitine for treatment of distal ulcerative colitis, Gastroenterology, 103, 1709, 10.1016/0016-5085(92)91215-P Johnson, 1993, l-carnitine for treatment of nonspecific proctosigmoiditis, Dis. Colon. Rectum., 36, 518, 10.1007/BF02050022 Wong, 2006, Colonic health: fermentation and short chain fatty acids, J. Clin. Gastroenterol., 40, 235, 10.1097/00004836-200603000-00015 Brown, 2003, The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids, J. Biol. Chem., 278, 11312, 10.1074/jbc.M211609200 Karaki, 2006, Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine, Cell Tissue Res., 324, 353, 10.1007/s00441-005-0140-x Canani, 2004, Butyrate as an effective treatment of congenital chloride diarrhea, Gastroenterology, 127, 630, 10.1053/j.gastro.2004.03.071 Matthews, 1998, Na-K-2Cl cotransporter gene expression and function during enterocyte differentiation. Modulation of Cl- secretory capacity by butyrate, J. Clin. Invest., 101, 2072, 10.1172/JCI1042 Heimerl, 2006, Alterations in intestinal fatty acid metabolism in inflammatory bowel disease, Biochim. Biophys. Acta, 1762, 341, 10.1016/j.bbadis.2005.12.006 Famularo, 2004, Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation, Ann. N.Y. Acad. Sci., 1033, 132, 10.1196/annals.1320.012 Andrieu-Abadie, 1999, l-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation, Faseb J., 13, 1501, 10.1096/fasebj.13.12.1501 Amat di San Filippo, 2003, Functional domains in the carnitine transporter OCTN2, defective in primary carnitine deficiency, J. Biol. Chem., 278, 47776, 10.1074/jbc.M307911200 Amat di San Filippo, 2006, Pharmacological rescue of carnitine transport in primary carnitine deficiency, Hum. Mutat., 27, 513, 10.1002/humu.20314 Nakanishi, 2001, Na+- and Cl−-coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes, J. physiol., 532, 297, 10.1111/j.1469-7793.2001.0297f.x Babusukumar, 2006, Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn’s disease, Am. J. Gastroenterol., 101, 1354, 10.1111/j.1572-0241.2006.00564.x